A team led by investigators from Massachusetts General Hospital used a new drug to save the life of a patient with immune thrombotic thrombocytopenic purpura (iTTP), a rare disorder characterized by uncontrolled clotting throughout the small blood vessels. The group describes the first clinical use of the drug for iTTP in the New England Journal of Medicine. “The drug is a genetically engineered version of the missing enzyme in iTTP, and we showed that it was able to reverse the disease process in a patient with an extremely severe form Read More
HEALTH DAILY NEWS
Health News, Medical News, Medical conditions, Medical Tests & Procedures, Symptoms, Medical Diagnosis , Health Information, FDA alerts, Drug Watch, Product Watch, Medicine Articles, Welfare, Living